Find Immunology Drugs in Phase II Clinical Development in SWEDEN

Lead Product(s): Rabeximod

Therapeutic Area: Immunology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

This proactive and strategic decision follows the initiation of preparatory work for substance capsulation that started early this year and is part of the Phase IIb program.

Lead Product(s): Imlifidase

Therapeutic Area: Immunology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The completion of enrollment in the anti-GBM study marks an important milestone for the Company's expansion outside transplantation.